logo BDSP

Base documentaire


  1. Coagulation and fibrinolysis markers and risk of dementia : The Dutch vascular factors in dementia study.

    Article - En anglais

    We performed a cross-sectional case-control - study among 277 subjects with dementia and 298 control subjects drawn from participants of the Rotterdam Study, a population-based cohort study among subjects aged 55 years or over, and from participants of the Rotterdam Stroke Databank, a hospital-based stroke registry, with the objective to evaluate the association of indicators of coagulability, fibrinogen, prothrombin fragments 1+2, thrombin-antithrombin complex (TAT), and indicators of fibrinolysis, plasmin-inhibitor complex, D-dimer and tissue-type plasminogen activator (t-PA) with dementia.

    Increased levels of TAT, D-dimer and t-PA activity were associated with an increased risk of dementia.

    Additional stratified analyses indicated that an increased TAT level was the primary factor related to dementia.

    The present study provides evidence that predominantly increased thrombin generation is associated with dementia.

    Mots-clés Pascal : Démence Alzheimer, Trouble cognition, Démence vasculaire, Facteur risque, Epidémiologie, Marqueur biologique, Coagulation sanguine, Fibrinolyse, Dimère D, Prothrombine, Facteur coagulation, Fragment peptidique, Thrombine, Antithrombine, Complexe enzyme inhibiteur, Plasmin, Serine endopeptidases, Peptidases, Hydrolases, Enzyme, Plasmine inhibiteur, Pays Bas, Europe, Etude cas témoin, Homme, Système nerveux pathologie, Système nerveux central pathologie, Encéphale pathologie, Maladie dégénérative, Appareil circulatoire pathologie, Vaisseau sanguin pathologie

    Mots-clés Pascal anglais : Alzheimer disease, Cognitive disorder, Vascular dementia, Risk factor, Epidemiology, Biological marker, Blood coagulation, Fibrinolysis, D dimer, Prothrombin, Coagulation factor, Peptide fragment, Thrombin(drug), Antithrombin, Inhibitor enzyme complex, Plasmin, Serine endopeptidases, Peptidases, Hydrolases, Enzyme, Plasmin inhibitor, Netherlands, Europe, Case control study, Human, Nervous system diseases, Central nervous system disease, Cerebral disorder, Degenerative disease, Cardiovascular disease, Vascular disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0404021

    Code Inist : 002B17G. Création : 22/03/2000.